Regarding future directions in evaluating evantumumab in colorectal cancer CRC

Evantumumab (amivantamab)as a new type of EGFR inhibitor, has gradually attracted attention in the field of colorectal cancer (CRC) treatment in recent years. According to the latest research results of the OrigAMI-1 phase 1b/2 trial (NCT05379595) announced in 2025, evantumumab was evaluated as a single-agent treatment for patients with advanced or metastatic colorectal cancer, showing certain clinical effects compared with traditional standard-of-care chemotherapy or no standard chemotherapy.

In the trial, 23 patients who received evantumumab monotherapy achieved an objective response rate (ORR) of 22% (95% CI, 8%-44%) after a median follow-up of 8.1 months, indicating a significant response in a number of patients. At the same time, the median duration of response (DOR) was 9.8 months (95% CI, 3.7-not evaluable [NE]), reflecting the good efficacy of some patients after receiving treatment. In addition, the disease control rate (DCR) was 78% (95% CI, 56%-93%) and the progression-free survival (PFS) was 3.7 months (95% CI, 3.4-5.5). These results show that evantumumab has potential therapeutic value in specific populations.

In the treatment group that combined evantumumab withFOLFOX or FOLFIRI, the researchers observed more prominent effects. At a median follow-up of 8.2 months (range, 3.2-11.9), the ORR in 7 patients was as high as 43% (95% CI, 10%-82%), while the median DOR lacked sufficient data to evaluate, but the DCR reached 86% (95% CI, 42%-100%), and the median PFS was 7.4 months (95% CI, 1.8-NE). These data suggest that evantuzumab may improve treatment efficacy when combined with other chemotherapy regimens, especially in patients who have poor response to traditional chemotherapy, showing its potential superiority.

With the success of the OrigAMI-1 trial, the clinical development space for colorectal cancer is continuing to expand. The research team has initiated a new series of Phase 3 clinical trials to further evaluate evantumumab in the treatment of metastatic colorectal cancer. Among them, the OrigAMI-2 trial (NCT06662786) will focus on evaluating the effect of evantumumab in combination with cetuximab, either with or without chemotherapy as first-line treatment. The exploration of this combination treatment strategy may provide more effective treatment options for patients with metastatic CRC. At the same time, the OrigAMI-3 trial (NCT06750094) is also ongoing, aiming to further verify the clinical application of evantumumab.

In addition to its application in colorectal cancer, evantumumab is also considered to have potential clinical value in other tumor types, especially those gastrointestinal cancers that are sensitive to EGFR inhibitors. In this context, continued evaluation of the indications and efficacy of evantumumab will bring new hope to different patient groups.

In addition, further research on biomarkers is also an important direction in the future. In the OrigAMI-1 trial, patients showed multiple genomic alterations known to be resistant to EGFR inhibitors, including mutations in TP53, APC, MAP2K1, ATM, ARID1A, PIK3CA, RB1, PTEN, KRAS, FBXW7, EGFR, CDKN2A and BRAF. These genomic changes not only reveal the complexity of drug resistance mechanisms, but also provide researchers with a basis for in-depth understanding of patient differences in response to treatment.

Research on these drug resistance genes can provide new ideas for overcoming the resistance of colorectal cancer to first-generation EGFR inhibitors. For example, targeting these resistance mutations or using combination therapies to enhance treatment effects are all directions worth exploring. Therefore, future research needs to focus on how to develop personalized treatment plans through precision medicine to overcome the limitations of existing treatments.

Reference materials:https://www.onclive.com/view/dr-pietrantonio-on-future-directions-of-evaluating-amivantamab-in-crc